A recombinant Getah Virus expressing a GFP gene for rapid neutralization testing and antiviral drug screening assay.

Overview

• This research developed a genetically engineered Getah virus that expresses a glowing protein to quickly test virus neutralization and screen antiviral drugs.
• The study showed the virus’s ability to help identify potential treatments, including demonstrating ivermectin’s inhibitory effect on the virus in cell cultures.

Background on Getah Virus (GETV)

• GETV is a mosquito-transmitted RNA virus that affects animals like horses and pigs.
• In horses, it causes fever, swelling in limbs and lymph nodes, and skin rashes.
• Pigs infected with GETV experience stillbirths in pregnant sows and neurological issues leading to death in piglets.
• Currently, no specific antiviral treatments or drugs exist for GETV infections.

Purpose and Significance of the Study

• Researchers aimed to create a version of the virus that carries a fluorescent reporter gene, enabling real-time monitoring of viral replication and spread.
• Using fluorescent markers simplifies and speeds up virus neutralization tests (VNTs), which are important for evaluating immune responses and antiviral drug effectiveness.
• Such reporter viruses are powerful tools for studying viral life cycles and identifying stages vulnerable to therapeutic agents.

Methodology: Construction of Recombinant Viruses

• Two recombinant GETV strains were engineered by inserting reporter genes at an unreported site — the 3′ end of the structural protein gene — allowing stable incorporation of foreign genes.
• The two viruses created were rGEEiLOV (expressing a different fluorescent protein) and rGEEGFP (expressing Green Fluorescent Protein, GFP).
• These recombinant viruses were tested in BHK-21 cells, a standard cell line used for virus culture and replication studies.
• Genetic stability was confirmed for at least five replication cycles (passages), ensuring durability of the inserted reporter genes.
• Both recombinant viruses replicated at rates comparable to the original, unmodified GETV, indicating that the insertion did not impair viral fitness in vitro.

Application: Viral Neutralization Testing and Antiviral Screening

• The rGEEGFP virus proved particularly useful for performing viral neutralization tests, as GFP fluorescence can be monitored rapidly and quantitatively, avoiding lengthy traditional assays.
• The fluorescent signal allowed for easy tracking of viral infection and inhibition in infected cells, facilitating efficient screening of antiviral compounds.
• Using this system, researchers tested ivermectin, a broad-spectrum antiparasitic drug, for its ability to inhibit GETV.
• Ivermectin demonstrated an effect in vitro by interfering with early replication stages of GETV within cells.
• The drug also blocked cell-to-cell transmission of the virus, an important feature that could limit viral spread within an organism.

Conclusions and Future Implications

• The study successfully created fluorescent GETV strains that serve as valuable tools for drug discovery and neutralization assays.
• The rGEEGFP virus, in particular, offers a rapid, reliable, and visually trackable method to assess both immune responses and antiviral agent efficacy.
• Identification of ivermectin’s anti-GETV activity suggests potential therapeutic avenues and encourages further investigation of drugs targeting early viral replication.
• The approach could be extended to screen other candidate inhibitors, supporting the development of specific treatments against GETV, which currently lacks effective therapies.
• Overall, this research contributes essential tools and preliminary findings towards controlling and mitigating the impact of this re-emerging viral pathogen.